Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Solid Tumor 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

Azacitidine 38Cytarabine 37venetoclax 35fludarabine 28Cyclophosphamide 21Daunorubicin 18fludarabine phosphate 17Decitabine 17Specimen Handling 15Tacrolimus 14Injections 13Busulfan 13Biopsy 12Melphalan 11Granulocyte Colony-Stimulating Factor 11CPX-351 11Mycophenolic Acid 10Idarubicin 10Stem Cell Transplantation 9Whole-Body Irradiation 8Etoposide 8decitabine and cedazuridine drug combination 7Thiotepa 7Mitoxantrone 7enasidenib 6Peripheral Blood Stem Cell Transplantation 6Methotrexate 6ivosidenib 5gilteritinib 5Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myeloid, Acute × cedazuridine × Clear all
NCT04657081 2025-12-08

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
101 enrolled 1 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡